Calcitonin, a hormone that lowers calcium levels in the blood and prevents bone loss, has only been available in an injectable and nasally-administered format to date. New research by Conway investigator, Dr David Brayden promises to ultimately deliver an oral method of treating osteoporosis patients with this hormone, which would have many advantages over current treatment regimes.
All drugs taken orally face the same problem; they must get from the gut into the bloodstream and avoid being broken down by enzymes before they can carry out their job. This is no mean task for many drugs, but it is especially problematic for peptides, some of the main products of the pharmaceutical industry. Dr David Brayden, who is based in the Faculty of Veterinary Medicine, University College Dublin has suggested a method for delivering calcitonin into the bloodstream by the oral route. The research involves attaching calcitonin to a novel sticky polymer and incorporating components that will both prevent the breakdown of calcitonin and help it move across the gut wall.
Science Foundation Ireland recently awarded Dr Brayden substantial funding under their investigator programme grant scheme to develop his research. Dr. Brayden was formerly a senior research scientist with Elan Corporation before moving to University College Dublin in 2001.
Elaine Quinn | alfa
Malaria Already Endemic in the Mediterranean by the Roman Period
27.07.2017 | Universität Zürich
Serious children’s infections also spreading in Switzerland
26.07.2017 | Universitätsspital Bern
26.07.2017 | Event News
21.07.2017 | Event News
19.07.2017 | Event News
28.07.2017 | Life Sciences
28.07.2017 | Information Technology
28.07.2017 | Physics and Astronomy